Presenting on the above topic is Mr Svend Licht, Senior Director, Novozymes Biopharma, Denmark. He will be speaking at Biologic Manufacturing World Asia 2012, part of a series of conferences in the 5th Annual BioPharma Asia Convention 2012, held on 19-22 March at Marina Bay Sands, Singapore.
Mr Svend Licht joined Novo in 1986 working with economy and production planning activities in the Bio-chemicals Division. From there he moved on as manager for the planning function of International Operations for the enzyme business in Novo Nordisk, building up the international planning systems and procedures for the industrial enzyme organisation. In 1994 he went to Paris as sales support director for the European enzyme business and in 1999 he took over the position as sales director and general manager for Middle East & Africa based out of Greece. He returned to Denmark in 2001 as senior director in the newly established Biotech Business Devel-opment group in Novozymes. This group was established to be an incubator for new business ideas for Novozymes developed through internal R&D projects, corporate partnering and acquisition activi-ties. His current role includes strategy development as well as general business development activities within commecialisation of technologies and solutions to the biopharmaceutical industry. In his recent positions he has been responsible for the completion of several international acquisitions and the management of numerous other deal processes.
Prior to joining Novo, he worked as a chemical plant process engineer at Haldor Tops?e, Denmark (1985-1986). He holds a BSc in chemical engineering from the technical university in Copenhagen, a BSc in foreign trade from Copenhagen Business School and an executive MBA with distinction from Ashridge Management College in UK. He is Novozymes? representative in Corporate Strategy Board (an international forum for sharing of better practises). Svend is a speaker at conferences on the topics of a.o. strategy, acquisition and industrial biotechnology. He is the chairman of board for Wiseled – a Danish start-up company active development and com-mercialisation of innovative professional flashlights (www.wiseled.com). Further to this he is also on the board of Unisensor (www.unisensor.dk) a danish company specialising in optical analysis in the medical, veterinary and biotechnological segments.
Mr Licht will be addressing the following topics:
Utilising emerging technologies to develop commercially scalable manufacturing platforms for biotherapeutic production
1. Developing albumin based half-life extension strategies for protein therapeutics
2. Implementing drug delivery strategies using albumin
3. Tailoring Half Life with Albufuse(r)Flex – Developing next generation albumin fusion and conjugation based on modified albumin